Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. (PubMed, Am J Hematol) - Mar 12, 2025 - "While letermovir prophylaxis is available for CMV-seropositive recipients, optimal donor selection for CMV-seronegative recipients remains unclear, with donor age often prioritized over CMV serostatus. We investigated the relative impact of donor age and CMV serostatus in CMV-seronegative recipients (n = 1013) with either CMV-seropositive (n = 318) or CMV-seronegative donors (n = 695), who underwent HCT with HLA-matched sibling donors with calcineurin inhibitor-based or post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis, or haploidentical donors with PTCy...Our findings suggest that prioritizing a CMV-seronegative donor may be associated with improved outcomes in CMV-seronegative recipients. Further research is needed to validate these findings and explore underlying mechanisms."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Aleksandr Lazaryan; Annie Im; Anurag Singh; Bryan Huber; Christopher G Kanakry; Dimana Dimitrova; Elisabetta Xue; Filippo Milano; Gabriela S Petitto; Hannah Choe; Jennifer Kanakry; Jennifer Saultz; Mustafa Hyder; Prashant Sharma; Rohtesh S Mehta; Shannon McCurdy; Taha Al-Juhaishi; Yosra M Aljawai; Zimu Gong
|